Terms: = Ovarian cancer AND NRAS, N-ras, 4893, ENSG00000213281, P01111, NRAS1 AND Diagnosis
19 results:
1. De novo myeloid sarcoma mimicking gynecological tumors: a retrospective case series of eight patients.
Gu Y; Zheng H; Mo S; Guo T; Chen L; Yang J; Xiang Y
BMC Womens Health; 2023 Mar; 23(1):141. PubMed ID: 36978050
[TBL] [Abstract] [Full Text] [Related]
2. Genomic profiling in low grade serous ovarian cancer: Identification of novel markers for disease diagnosis and therapy.
ElNaggar A; Robins D; Baca Y; Arguello D; Ulm M; Arend R; Mantia-Smaldone G; Chu C; Winer I; Holloway R; Krivak T; Jones N; Galvan-Turner V; Herzog TJ; Brown J
Gynecol Oncol; 2022 Nov; 167(2):306-313. PubMed ID: 36229265
[TBL] [Abstract] [Full Text] [Related]
3. PRAME Expression in cancer. A Systematic Immunohistochemical Study of >5800 Epithelial and Nonepithelial Tumors.
Kaczorowski M; Chłopek M; Kruczak A; Ryś J; Lasota J; Miettinen M
Am J Surg Pathol; 2022 Nov; 46(11):1467-1476. PubMed ID: 35973038
[TBL] [Abstract] [Full Text] [Related]
4. Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22).
Musacchio L; Califano D; Bartoletti M; Arenare L; Lorusso D; Losito NS; Cormio G; Greggi S; Raspagliesi F; Valabrega G; Salutari V; Pisano C; Spina A; Russo D; Del Sesto M; Canzonieri V; Ferraù F; Zannoni GF; Loizzi V; Ghizzoni V; Casanova C; Tuninetti V; Ducceschi M; Del Vecchio V; Scalone S; Priolo D; Perrone F; Scambia G; Pignata S
Br J Cancer; 2022 Nov; 127(8):1479-1486. PubMed ID: 35869143
[TBL] [Abstract] [Full Text] [Related]
5. The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes.
Gershenson DM; Sun CC; Westin SN; Eyada M; Cobb LP; Nathan LC; Sood AK; Malpica A; Hillman RT; Wong KK
Gynecol Oncol; 2022 Jun; 165(3):560-567. PubMed ID: 35606067
[TBL] [Abstract] [Full Text] [Related]
6. MAPK Pathway Genetic Alterations Are Associated with Prolonged Overall Survival in Low-Grade Serous ovarian Carcinoma.
Manning-Geist B; Gordhandas S; Liu YL; Zhou Q; Iasonos A; Da Cruz Paula A; Mandelker D; Long Roche K; Zivanovic O; Maio A; Kemel Y; Chi DS; O'Cearbhaill RE; Aghajanian C; Weigelt B; Chui MH; Grisham RN
Clin Cancer Res; 2022 Oct; 28(20):4456-4465. PubMed ID: 35443055
[TBL] [Abstract] [Full Text] [Related]
7. Molecular assessment of testicular adult granulosa cell tumor demonstrates significant differences when compared to ovarian counterparts.
Siegmund S; Sholl LM; Cornejo KM; Sangoi AR; Otis CN; Mehra R; Hirsch MS; Acosta AM
Mod Pathol; 2022 May; 35(5):697-704. PubMed ID: 34845303
[TBL] [Abstract] [Full Text] [Related]
8. N6-Methyladenosine-Related RNA Signature Predicting the Prognosis of ovarian cancer.
Jiao J; Jiang L; Luo Y
Recent Pat Anticancer Drug Discov; 2021; 16(3):407-416. PubMed ID: 34137363
[TBL] [Abstract] [Full Text] [Related]
9. Next-generation sequencing-based genomic profiling analysis reveals novel mutations for clinical diagnosis in Chinese primary epithelial ovarian cancer patients.
Zhang L; Luo M; Yang H; Zhu S; Cheng X; Qing C
J Ovarian Res; 2019 Feb; 12(1):19. PubMed ID: 30786925
[TBL] [Abstract] [Full Text] [Related]
10. Targeted sequencing with a customized panel to assess histological typing in endometrial carcinoma.
Cuevas D; Valls J; Gatius S; Roman-Canal B; Estaran E; Dorca E; Santacana M; Vaquero M; Eritja N; Velasco A; Matias-Guiu X
Virchows Arch; 2019 May; 474(5):585-598. PubMed ID: 30710169
[TBL] [Abstract] [Full Text] [Related]
11. A rare case of synchronous ovarian tumors: clinical case report and literature review.
Roşu GA; Furău GO; Ionescu CA; Dimitriu MCT; Neacşu A; Ioan RG; Călin FD; Matei A; Bănacu M; Popescu I; Gheorghiu D; Neacşu I; Bacalbaşa N; Furău CG
Rom J Morphol Embryol; 2019; 60(4):1365-1370. PubMed ID: 32239119
[TBL] [Abstract] [Full Text] [Related]
12. Testing for
Sadlecki P; Grzanka D; Grabiec M
Dis Markers; 2018; 2018():1497879. PubMed ID: 29682098
[TBL] [Abstract] [Full Text] [Related]
13. Associations between primary tumor RAS, BRAF and PIK3CA mutation status and metastatic site in patients with chemo-resistant metastatic colorectal cancer.
Christensen TD; Palshof JA; Larsen FO; Poulsen TS; Høgdall E; Pfeiffer P; Jensen BV; Yilmaz MK; Nielsen D
Acta Oncol; 2018 Aug; 57(8):1057-1062. PubMed ID: 29380640
[TBL] [Abstract] [Full Text] [Related]
14. Molecular diagnosis in type I epithelial ovarian cancer.
Sadłecki P; Walentowicz-Sadłecka M; Grabiec M
Ginekol Pol; 2017; 88(12):692-697. PubMed ID: 29303228
[TBL] [Abstract] [Full Text] [Related]
15. Whole-exome sequencing of duodenal adenocarcinoma identifies recurrent Wnt/β-catenin signaling pathway mutations.
Yuan W; Zhang Z; Dai B; Wei Q; Liu J; Liu Y; Liu Y; He L; Zhou D
Cancer; 2016 Jun; 122(11):1689-96. PubMed ID: 26998897
[TBL] [Abstract] [Full Text] [Related]
16. Mutational status of KRAS, nras, and BRAF in primary clear cell ovarian carcinoma.
Zannoni GF; Improta G; Chiarello G; Pettinato A; Petrillo M; Scollo P; Scambia G; Fraggetta F
Virchows Arch; 2014 Aug; 465(2):193-8. PubMed ID: 24889043
[TBL] [Abstract] [Full Text] [Related]
17. Ras gene activation in malignant cells of human ovarian carcinoma peritoneal fluids.
Dokianakis DN; Varras MN; Papaefthimiou M; Apostolopoulou J; Simiakaki H; Diakomanolis E; Spandidos DA
Clin Exp Metastasis; 1999 Jun; 17(4):293-7. PubMed ID: 10545015
[TBL] [Abstract] [Full Text] [Related]
18. [Amplification of proto-oncogenes C-myc, C-n-ras, C-Ki-ras, C-erbB2 in ovarian carcinoma].
Bian M; Fan Q; Huang S
Zhonghua Fu Chan Ke Za Zhi; 1995 Jul; 30(7):406-9. PubMed ID: 7587576
[TBL] [Abstract] [Full Text] [Related]
19. Genetic analysis of germ cell tumors: current progress and future prospects.
Ilson DH; Bosl GJ; Motzer R; Dmitrovsky E; Chaganti RS
Hematol Oncol Clin North Am; 1991 Dec; 5(6):1271-83. PubMed ID: 1663944
[TBL] [Abstract] [Full Text] [Related]
